Major Shareholder Announcement
Announcement no. 6/2016
To Nasdaq Copenhagen
22 March 2016
Major shareholder announcement
Exiqon A/S, listed on Nasdaq Copenhagen ("EXQ"), has been informed that Danske Bank Group - includingr Danica Pension and Danske Invest FCP Invest- after sale of shares owns less than 5% of the share capital and voting rights in Exiqon A/S.
Additional information
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)
About Exiqon
At Exiqon, we advance the research of when and where genes are expressed. We empower scientists across the world with best-in-class products and user-friendly business solutions designed to transform workflows in our industry. Exiqon operates in two business areas: Exiqon Life Sciences is a leading provider of flexible solutions for gene expression analysis. Academia, biotech and pharmaceutical companies around the world use Exiqon's research products to make ground-breaking discoveries. Exiqon Diagnostics collaborates with diagnostic and pharmaceutical companies to develop novel molecular diagnostic tests for early detection of diseases, which can help physicians make better treatment decisions. Exiqon is listed on Nasdaq Copenhagen. For more information about us, please visit www.exiqon.com
Vedhæftede filer:
Announcement_6_2016_major_shareholder_announcement.pdf